Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis

M E C Jeurissen, A M Th Boerbooms, L B A van de Putte, M W M Kruijser

Abstract
Within one year three of 25 patients with rheumatoid arthritis treated with azathioprine 100 mg daily developed the following adverse reactions less than two weeks after starting treatment: patient one showed fever with chills, rash, and severe liver function abnormalities suggestive of cholestasis; the second patient had fever, nausea, diarrhoea, and moderately raised liver enzymes; the third patient showed very high fever and severe chills. In two patients the drug was rechallenged, with more rapidly arising and more severe symptoms. In one case raised liver enzymes persisted until seven months after discontinuation of azathioprine. Hypersensitivity reactions and hepatotoxicity of azathioprine are discussed.

Hypersensitivity reactions to azathioprine—for example, fever, myalgia, arthralgia, and rash—are well known, but rare, adverse reactions to the drug.1 To our knowledge the combination of liver function abnormalities with fever, chills, and rash has been reported before in only two patients.2 Recently, we observed in one year three patients with rheumatoid arthritis (RA) treated with 100 mg azathioprine daily who developed fever and chills with liver function abnormalities (two patients) and rash (one patient).

The clinical picture of these three patients is described and allergic adverse reactions to azathioprine and the hepatotoxicity of the drug are discussed.

Case reports

Case 1
A 49 year old man was diagnosed as having seropositive RA since 1977. He had been successively treated with parenteral gold and d-penicillamine. Both drugs were ineffective. For several years he also took diclofenac 150 mg daily. In April 1988 treatment with azathioprine (100 mg daily) was started because of active RA involving shoulders, elbows, hands, and feet. Laboratory findings were as follows: erythrocyte sedimentation rate (ESR) 42 mm/h and haemoglobin 130 g/l. Apart from an increased concentration of IgA 4.5 g/l (normal <2.6 g/l), other laboratory values were normal. Ten days after starting azathioprine he developed fever (38.5°C) with severe chills, diarrhoea, and dermatitis of his hands. Azathioprine was discontinued and laboratory values showed a greatly increased ESR of 108 mm/h, alkaline phosphatase 317 U/l (normal <120 U/l), and γ-glutamyltransferase 176 U/l (normal <40 U/l). Two days later the clinical situation worsened and he was admitted to hospital. Apart from severe dermatitis of his hands with vesicles and pustules and a moderately active RA, physical examination on admission was normal. Laboratory findings were as follows: ESR 93 mm/h, haemoglobin 120 g/l, leucocytes (including eosinophils) and platelets normal. Alkaline phosphatase 810 U/l, γ-glutamyltransferase 295 U/l, serum aspartate aminotransferase (AST) 127 U/l (normal <25 U/l), serum alanine aminotransferase (ALT) 150 U/l (normal <30 U/l). Bilirubin total and direct slightly raised at 26 and 18 μmol/l (normal <10 μmol/l and 1 μmol/l respectively), lactic dehydrogenase and amylase normal. Blood cultures showed no growth. Tests for syphilis, hepatitis A and B, and cytomegalovirus were negative. Antinuclear antibody, antibodies against mitochondria and smooth muscle were also negative. HLA typing: A2, B5, B15, Bw62, B4, Bw6, DR4, DRw52, DQw2, DQw3. Ultrasonography of gall bladder, biliary tract, liver, and pancreas was normal.

Because all liver enzymes rose further (maximum alkaline phosphatase 935 U/l, AST 290 U/l) a liver biopsy was performed. Histological examination showed only some (peri)portal infiltration and several necrotic liver cells, but neither cholestasis nor cirrhosis. The figure shows the course of the liver function tests. He was dismissed with diclofenac 150 mg. In July 1988 the RA was more active and prednisone 7.5 mg daily was started. The liver enzymes normalised only seven months after dismissal.

Case 2
A 63 year old woman had been suffering from seropositive RA since 1977. Besides indomethacin 150 mg daily she had been treated with hydroxychloroquine sulphate, d-penicillamine (thrombocytopenia), oral gold tablets (ineffective), and sulphasalazine (fever, exanthema). She refused parenteral gold treatment. In March 1987 she was admitted to hospital because of active RA involving knee, hands, wrists, and shoulders. The ESR was 97 mm/h, haemoglobin 115 g/l, IgA 4.9 g/l, IgG 16.3 g/l (normal <14.6 g/l). Other laboratory findings were normal. HLA typing: A2, Aw19, B13, B15, Bw4, Bw6, DR4, DR7, DRw53, DQw2, DQw3.

Thirteen days after starting azathioprine 100 mg daily she developed fever (39°C), nausea, vomiting, and diarrhoea. Blood tests showed raised alkaline phosphatase (240 U/l) and γ-glutamyltransferase (76 U/l). Blood cell counts were unchanged. Transaminase and amylase...
were normal. Blood cultures showed no growth. Ultrasonography of the abdomen was normal. Azathioprine was discontinued. Five days later one tablet of azathioprine was given by accident and within two hours diarrhoea and fever (39.5°C) again occurred. Liver enzymes returned to normal in two weeks. She was successfully treated with 15 mg methotrexate orally weekly. This drug caused no liver dysfunctions.

CASE 3
A 74 year old woman was diagnosed as suffering from seropositive RA since 1984. Besides diclofenac 100 mg daily she had been treated with parenteral gold for one year and d-penicillamine 750 mg daily for 18 months. Both drugs were ineffective. In October 1987 azathioprine 100 mg daily was started because of active RA involving wrists, hands, left shoulder, and jaws. Laboratory findings showed an ESR of 30 mm/h, C reactive protein 51.0 mg/l (normal <6-0 mg/l), haemoglobin 125 g/l. Apart from a diminished renal function (estimated creatinine clearance 60 ml/min) and raised IgA (4·1 g/l) and IgG (21·6 g/l), other laboratory values were normal. HLA typing: A2, A29, B12, B27, Bw4, Bw6, DR4, DQw2, DQw3. Patient 3 also had these phenotypes except B15 and DQw2. In 171 other patients with RA treated with different drugs we did not find the HLA typing of cases 1 and 2. We could not confirm an association between a low IgA concentration and azathioprine hepatotoxicity because the patients we described all had repeatedly raised IgA concentrations.

Hypersensitivity reactions to azathioprine have been found to occur mostly within two weeks of starting treatment. 

Discussion
Our finding of azathioprine hypersensitivity reactions in three of 25 (12%) patients with RA followed up for one year is remarkable. Bell et al (ARA meeting, Houston, May 1988) have also reported a high percentage of azathioprine hypersensitivity reactions (4/17; 24%). The presence of these side effects in larger numbers of patients with RA, our own previous study included, was between <1% and 5%. 1 3 4 7 To our knowledge the triad (severe liver function abnormalities, rash, fever with chills), as shown in patient 1, has been reported only once before in two out of a series of 50 patients with RA. 2 Hypersensitivity reactions or hepatotoxicity, or both, due to azathioprine have also been reported in patients with diseases other than RA. 6-10 Although a genetic predisposition to azathioprine toxicity is speculative, we found a striking similarity of HLA typing in patients 1 and 2, both having the phenotypes A2, B15, Bw4, Bw6, DR4, DQw2, DQw3. Patient 3 also had these phenotypes except B15 and DQw2. In 171 other patients with RA treated with different drugs we did not find the HLA typing of cases 1 and 2. We could not confirm an association between a low IgA concentration and azathioprine hepatotoxicity because the patients we described all had repeatedly raised IgA concentrations.

Hepatotoxicity associated with azathioprine can develop between two weeks and 33 months after starting treatment, 6-8 possibly depending on the origin of hepatotoxicity. The mechanisms of azathioprine hepatotoxicity may be threefold—namely (a) allergic (with simultaneous systemic allergic symptoms); (b) direct hepatotoxic (exact mechanism unknown 13); (c) blockade of the liver blood outflow at the junction of sinusoids and centrilobular veins, causing portal hepatitis. 13 Davis et al have suggested that the imidazole moiety of azathioprine causes the allergic symptoms and the 6-mercaptopurine moiety the liver injury. 10 Histologically, the picture of azathioprine hepatotoxicity consists of intrahepatic cholestasis with variable degrees of liver cell necrosis and slight (peri)portal inflammatory reaction. Biochemically, abnormal liver function tests are found, ranging between a cholestatic pattern and increase of transaminase. 6-12 Azathioprine hepatotoxicity is mostly a reversible process, but normalisation of liver enzymes can take several months, 8 as shown in patient 1. For different reasons it
Azathioprine induces fever and hepatotoxicity in RA

Azathioprine

seems unlikely that diclofenac had a role in the production of liver dysfunctions in patient 1. Firstly, he had already used that drug for several years without side effects. Secondly, liver function returned to normal (very slowly) while treatment with diclofenac was continuing. Thirdly, the pattern of liver enzyme increase (cholestatic) is unusual for diclofenac hepatotoxicity. In a smaller dose of azathioprine in dose related hepatotoxicity seems justified, but rechallenge of azathioprine when there is a suspicion of hypersensitivity can be dangerous and lead to life threatening shock. In patient 2 the reintroduction of azathioprine was not our intention but happened accidentally. Retrospectively, the first period of fever and malaise in patient 3 was not recognised as azathioprine toxicity. If there is a compelling reason for reintroducing azathioprine it must be done under very careful clinical observation. For completeness we point out that the spectrum of azathioprine hypersensitivity can include more symptoms.

In summary, with these three case reports of azathioprine hypersensitivity in patients with RA we draw attention to this serious complication and recommend that liver function tests are carried out two weeks after starting azathioprine and thereafter every one to two months.

Addendum

Very recently we saw a new case of severe azathioprine hypersensitivity in a patient whose clinical picture was similar to that of patient 1.

The patient, a 27 year old man who had had destructive seropositive RA since 1983, was admitted to hospital because of fever (39-2°C), chills, nausea, cough, and purpura on his legs. He had taken azathioprine 100 mg for 12 days and piroxicam 20 mg daily for several years. Both drugs were discontinued. Laboratory investigation of this severely ill patient disclosed an ESR of 126 mm/h (78 mm/h), (figures in brackets show the values before the start of azathioprine treatment), haemoglobin 101 g/l (127 g/l), leucocytes 27×10^9/l (11.8×10^9/l) with shift to the left in the differential count, bilirubin total 63 μmol/l, direct 46 μmol/l, azathioprine 422 U/l (77 U/l), γ-glutamyltransferase 73 U/l, ALT 87 U/l (8 U/l), AST 32 U/l (11 U/l). Chest radiograph was normal. Blood cultures showed no growth. All serological tests (see patient 1) were negative. Because all liver enzymes rose further in three weeks (alkaline phosphatase 800 U/l, γ-glutamyltransferase 175 U/l, ALT 192 U/l, AST 63 U/l) a liver biopsy was performed, which disclosed a moderate portal infiltration of eosinophil leucocytes around small bile canaliculi (without bile stasis). Sporadic necrotic liver cells were present. A skin biopsy showed aspecific perivascular inflammation. Six weeks after admission this patient is still in hospital (May 1989) and liver enzymes are still greatly raised (alkaline phosphatase 900 U/l, γ-glutamyltransferase 254 U/l, ALT 148 U/l). HLA typing: Aw19, B15, B40, Bw6, DR4, DQw3.

We are grateful to Dr M Kruisjes (Ziekenhuis Ziekenzorg, Eindhoven, The Netherlands) for allowing us to study his patients, and we wish to thank Mrs Marion Janssen for her excellent secretarial help.

Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis.

M E Jeurissen, A M Boerbooms, L B van de Putte and M W Kruijssen

doi: 10.1136/ard.49.1.25